Valuation: Icure Pharmaceutical Incorporation

Market Cap 63.6B 46.27M 40.34M 37.99M 34.6M 64.87M 4.43B 64.95M 455M 175M 2.26B 174M 170M 7.29B P/E 2024
64.8x
P/E 2025 -2.42x
Enterprise Value 80.25B 58.37M 50.9M 47.94M 43.65M 81.85M 5.59B 81.95M 574M 221M 2.85B 219M 214M 9.19B EV / Sales 2024
1.24x
EV / Sales 2025 1.17x
Free-Float
90.52%
Yield 2024 *
-
Yield 2025 -
08-27 Icure Pharmaceutical Incorporation announced that it has received KRW 24.999999266 billion in funding from Solum Cosmetic Co.,Ltd, Deep Dive Partners, Sinsin Pharmaceutical Co., Ltd CI
08-14 Icure Pharmaceutical Incorporation Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026 CI
05-15 Icure Pharmaceutical Incorporation Reports Earnings Results for the First Quarter Ended March 31, 2026 CI
03-30 Icure Pharmaceutical Incorporation Reports Earnings Results for the Full Year Ended December 31, 2025 CI
11-16 Huons Natural Co,Ltd. acquired Bio Rosette Co.,Ltd. CI
11-14 Icure Pharmaceutical Incorporation Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2025 CI
25-08-14 Icure Pharmaceutical Incorporation Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2025 CI
25-05-15 Icure Pharmaceutical Incorporation Reports Earnings Results for the First Quarter Ended March 31, 2025 CI
25-03-21 Icure Pharmaceutical Incorporation Reports Earnings Results for the Full Year Ended December 31, 2024 CI
24-12-26 Icure Pharmaceutical Incorporation announced that it has received KRW 9 billion in funding from Sangsangin Plus Savings Bank Co.,Ltd., Sangsangin Savings Bank CI
24-12-23 Icure Pharmaceutical Incorporation announced that it expects to receive KRW 9 billion in funding from Sangsangin Plus Savings Bank Co.,Ltd., Sangsangin Savings Bank CI
24-11-14 Icure Pharmaceutical Incorporation Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024 CI
24-08-14 Icure Pharmaceutical Incorporation Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2024 CI
1 day+7.45%
1 week-3.02%
Current month-21.57%
1 month-21.57%
3 months-21.57%
6 months-21.57%
Current year-21.57%
1 week 1,583
Extreme 1583
1,778
1 month 1,583
Extreme 1583
3,300
Current year 1,583
Extreme 1583
3,300
1 year 1,583
Extreme 1583
3,300
3 years 1,399
Extreme 1399
3,490
5 years 1,399
Extreme 1399
20,520.83
10 years 1,399
Extreme 1399
28,645.83
Manager TitleAgeSince
Chief Executive Officer 62 2022-03-30
Chief Executive Officer 66 -
Corporate Officer/Principal 52 2022-03-30
Director TitleAgeSince
Chairman 66 -
Director/Board Member 77 2022-03-30
Director/Board Member 52 2022-03-30
Date Insider Type Main position Quantity % Market Cap. Importance
5/20/24 Buy

Chief Executive Officer

3,637 0.0097%
Change 5-day change 1-year change 3-year change Capi.($)
+7.45%-3.02%-21.57%-28.19% 42.61M
+1.04%+2.34%+54.91%+111.75% 1,028B
-0.19%+1.18%+52.94%+66.69% 651B
+0.20%+1.04%+18.88%+72.38% 466B
+2.24%+0.94%+37.61%+45.31% 346B
+0.90%+1.95%+18.79%+25.27% 266B
+0.48%+3.34%+11.11%+15.38% 259B
+1.95%+3.06%+37.75%+45.93% 208B
-7.65%-5.95%-33.09%-60.76% 191B
+0.30%+2.83%+31.97%+100.03% 186B
Average +0.76%+2.78%+20.93%+39.38% 360.18B
Weighted average by Cap. +0.56%+3.09%+35.56%+65.24%

Financials

2024 2025
Net sales 69.21B 50.34M 43.89M 41.34M 37.65M 70.59M 4.82B 70.68M 495M 191M 2.46B 189M 185M 7.93B 83.38B 60.66M 52.89M 49.81M 45.36M 85.05M 5.81B 85.15M 597M 230M 2.96B 228M 223M 9.55B
Net income 1.2B 871K 760K 715K 652K 1.22M 83.46M 1.22M 8.57M 3.3M 42.51M 3.27M 3.2M 137M -33.6B -24.44M -21.31M -20.07M -18.28M -34.27M -2.34B -34.31M -240M -92.64M -1.19B -91.81M -89.78M -3.85B
Net Debt 18B 13.1M 11.42M 10.75M 9.79M 18.36M 1.25B 18.39M 129M 49.64M 639M 49.19M 48.1M 2.06B 16.64B 12.11M 10.56M 9.94M 9.05M 16.98M 1.16B 17M 119M 45.89M 591M 45.48M 44.47M 1.91B
Logo Icure Pharmaceutical Incorporation
Icure Pharmaceutical Incorporation is a Korea-based company mainly engaged in the production and sale of cosmetics. Along with subsidiaries, the Company operates its business through two segments. The Cosmetic segment is involved in the manufacturing and sale of cosmetics including basic cosmetics, mask packs, and patches. In addition, it is also engaged in the production and sale of body, hair care products and fragrances. The cosmetics are sold under the names of Botalinum, Mediheal N.M.F, Meditime, among others. The Pharmaceutical segment is engaged in the manufacturing and sale of over the counter (OTC) drugs, ethical the counter (ETC) drugs, as well as quasi drugs. The OTC drugs include anti-inflammatory analgesics and dementia treatments. The Company distributes its products within the domestic market and to overseas markets.
Employees
240
Date Price Change Volume
26-09-21 ₩1,702.00 +7.45% 412,459
26-09-18 ₩1,584.00 -4.12% 232,107
26-09-17 ₩1,652.00 -0.96% 74,254
26-09-16 ₩1,668.00 -3.42% 193,315
26-09-15 ₩1,727.00 -1.60% 118,187
  1. Stock Market
  2. Stocks
  3. A175250 Stock
-40%: Exceptional extension
d
:
:
SEIZE THE OFFER!